Skip to main content

#162347

Anti-cytoplasmic tail of CD4 [8A5]

Cat. #162347

Anti-cytoplasmic tail of CD4 [8A5]

Cat. #: 162347

Sub-type: Primary antibody

Unit size: 100 ug

Target: RFLPADQMNVADPQPLASCS of human CD4

Application: ELISA

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Brady Neal Ware

Institute: University of Georgia Research Foundation, Inc.

Primary Citation: Ware, 2003, Doctoral Thesis, University of Georgia. "Gene regulation and overlooked coding regions : the case for translation past the 3'-UGA codon in CD4"

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-cytoplasmic tail of CD4 [8A5]
  • Tool sub type: Primary antibody
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA
  • Description: Antibody developed against a region of CD4 that is only produced if the UGA is read through. Used to determine whether or not the first UGA codon in the 3' region of CD4 is read through in vivo.
  • Immunogen: Peptide
  • Isotype: IgM

Target Details

  • Target: RFLPADQMNVADPQPLASCS of human CD4
  • Target background: Amino acids 18-38 past the UGA that may end CD4, includes the predicted alpha helix sequence PADQ. Molecular weight of the peptide for the region past the UGA codon is 2160.6 Daltons. Peptide for the region past the UGA has 10 hydrophilic resides

Applications

  • Application: ELISA

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Ware, 2003, Doctoral Thesis, University of Georgia. "Gene regulation and overlooked coding regions : the case for translation past the 3'-UGA codon in CD4"

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.